Becton Dickinson and Company stock page - price, fundamentals, dividends - iOCharts

BDX

260.42
-2.20 (-0.84%)
Becton Dickinson and Company (NYSE, USD)
Healthcare >
Medical Instruments & Supplies
Market cap
74.79B
Ent value
102.70B
Price/Sales
4.11
Price/Book
3.16
Div yield
1.34%
Div growth
4.39%
Growth years
49
FCF payout
29.87%
Trailing P/E
46.74
Forward P/E
21.00
PEG
9.35
EPS growth
-8.90%
1 year return
-0.13%
3 year return
3.32%
5 year return
8.47%
10 year return
13.30%
Last updated: 2022-01-19

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open261.67
Daily high262.37
Daily low258.04
Daily Volume1.48M
All-time high285.99
1y analyst estimate268.13
Beta0.71
EPS (TTM)5.51
Dividend per share3.48
Ex-div date9 Dec 2021
Next earnings date4 Nov 2021

Downside potential

Loading...
Downside potential data
BDXS&P500
Current price drop from All-time high-8.94%-4.44%
Highest price drop-52.27%-56.47%
Date of highest drop26 Sep 20009 Mar 2009
Avg drop from high-11.59%-11.36%
Avg time to new high17 days12 days
Max time to new high1331 days1805 days

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share3.48
Dividend yield1.34%
Payout frequencyQuarterly
Maximum yield1.71%
Average yield1.34%
Minimum yield1.10%
Discount to avg yield-0.09%
Upside potential-0.09%
Yield as % of max yield77.96%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield1.34%
Current yield distribution45.48%
Yield at 100% (Min)1.10%
Yield at 90%1.21%
Yield at 80%1.24%
Yield at 50% (Median)1.33%
Yield at 20%1.41%
Yield at 10%1.51%
Yield at 0% (Max)1.71%

Dividend per share

Loading...
Dividend per share data
Years of growth49 years
CCC statusDividend Champion
Dividend per share3.48
Payout frequencyQuarterly
Ex-div date9 Dec 2021
EPS (TTM)5.51
EPS (1y forward)12.40
EPS growth (5y)-8.90%
EPS growth (5y forward)5.00%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
BDXS&P500
DGR MR4.82%14.59%
DGR TTM5.00%0.48%
DGR 3 years3.62%3.88%
DGR 5 years4.39%4.73%
DGR 10 years7.18%8.30%
DGR 15 years9.26%5.82%
Time since last change announced77 days
EPS growth (5y)-8.90%
EPS growth (5y forward)5.00%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM64.88%29.87%
Average--
Forward28.06%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E46.74
Price to OCF17.16
Price to FCF21.52
Price to EBITDA18.49
EV to EBITDA25.39

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.11
Price to Book3.16
EV to Sales5.64

FINANCIALS

Per share

Loading...
Per share data
Current share count287.19M
EPS (TTM)5.51
FCF per share (TTM)11.96

Income statement

Loading...
Income statement data
Revenue (TTM)18.21B
Gross profit (TTM)8.33B
Operating income (TTM)2.46B
Net income (TTM)1.60B
EPS (TTM)5.51
EPS (1y forward)12.40

Margins

Loading...
Margins data
Gross margin (TTM)45.76%
Operating margin (TTM)13.48%
Profit margin (TTM)8.79%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash2.28B
Net receivables2.50B
Total current assets8.84B
Goodwill36.68B
Intangible assets0.00
Property, plant and equipment0.00
Total assets53.87B
Accounts payable0.00
Short/Current long term debt17.61B
Total current liabilities500.00M
Total liabilities30.19B
Shareholder's equity23.68B
Net tangible assets-13.01B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)4.36B
Capital expenditures (TTM)883.00M
Free cash flow (TTM)3.48B
Dividends paid (TTM)1.04B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity6.49%
Return on Assets2.92%
Return on Invested Capital3.77%
Cash Return on Invested Capital8.18%
COMPANY DETAILS
BDX (Becton Dickinson and Company) company logo
Marketcap
74.79B
Marketcap category
Large-cap
Description
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Employees
0
Investor relations
SEC filings
CEO
Thomas Polen
Country
USA
City
Franklin Lakes
Stock type
Common stock
CCC status
Dividend Champion
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Investment company TRH Financial, LLC (Current Portfolio) buys Atmos Energy Corp, Kimberly-Clark Corp, Becton, Dickinson and Co, Coca-Cola Co, Johnson & Johnson, sells SPDR Portfolio S&P 400 Mid Cap E...
January 18, 2022
Parsippany, NJ, based Investment company NuWave Investment Management, LLC (Current Portfolio) buys Oracle Corp, Deere, ViacomCBS Inc, HubSpot Inc, Becton, Dickinson and Co, sells Johnson Controls Int...
January 18, 2022
Rating Action: Moody's assigns Ba3 CFR to Embecta Corp.; outlook stableGlobal Credit Research - 14 Jan 2022New York, January 14, 2022 -- Moody's Investors Service ("Moody's") assigned first time ratin...
January 14, 2022
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
January 14, 2022
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic buyouts.
January 11, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it was named to the JUST 100 list of America's most just companies by JUST Capital and its ...
January 11, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with Pfizer Inc. and global charitable foundation Wellcome to better unders...
January 11, 2022
Does the January share price for Becton, Dickinson and Company ( NYSE:BDX ) reflect what it's really worth? Today, we...
January 11, 2022
Regulatory clearance for BD's (BDX) Kiestra IdentifA system is expected to lead to better patient management via automated sample processing and MALDI target preparation.
January 10, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for ...
January 7, 2022
Next page